Cosmo Intelligent Medical Devices

Cosmo IMD develops cutting-edge Intelligent Medical Devices to empower physicians and improve patients’ lives.   Visit our website to learn how we are pioneering human-AI collaboration. www.cosmoimd.com #cosmoimd #gigenius #ai #artificialintelligence #aihealthcare #medicaldevices #medtech #colorectalcancer #colonoscopy #endoscopy

Last week, I had the honor of attending the NVIDIA Medical Device Meetup at Orsi Academy. The event was a dynamic mix of presentations, networking, and discussions about the revolution in healthcare with #ArtificialIntelligence. During the event, I presented "Bringing AI to the Patient Range," exploring how #AI reaches its full potential at supporting physicians when integrated into patient procedures, a topic at the heart of Cosmo Intelligent Medical Devices' mission. It was exciting to highlight our recent #FDA clearance for the latest hardware generation of our real-time AI platform, now based on NVIDIA IGX, a significant milestone in our partnership with NVIDIA. The panel discussion explored overcoming barriers to enabling software-defined medical devices, a theme central to Cosmo Intelligent Medical Devices and NVIDIA's vision. Our collaboration is paving the way for a medical device industry revolution. After Thijs Lowagie's warm welcome, it was inspiring and resonant to hear from David Niewolny about NVIDIA MedTech strategy, with Mostafa Toloui and Andreas Keil updating on our well-established pillars of Holoscan and IGX and how they come with an enterprise stack that enables the creation of mature and robust platforms. Then, as NVIDIA has gotten us used to, I enjoyed the burst of gunfire of technology updates from Oliver Kutter, Maximilian Ofir, Mikael Brudfors, Zhijin LI, and François REMY. It was fantastic to hear also other partners' presentations on technologies that are transforming the landscape. The event reinforced the immense potential of our mission, and I look forward to what lies ahead as we continue to push the boundaries of AI in healthcare. #AI #MedicalDevices #Innovation #CosmoIMD #NVIDIA #FDA #Partnerships #Medtech

Yesterday was a landmark day for Cosmo Pharmaceuticals as we hosted our first Company Day at one of our facilities in Lainate! With over 500 people in attendance – colleagues, families, and friends – it was a day filled with fun, engagement, inclusivity, and, above all, a shared excitement for the journey ahead. A special highlight was our founder, Mauro Ajani, delivering a powerful speech on the importance of collaboration and fostering a culture rooted in execution and happiness. His insights were truly inspiring, setting the tone for what we aim to achieve together as a team. As the new CEO, I am honored to lead this exceptional organization on a path of growth driven by talent and collaboration. Every day, I am inspired by the passion and dedication of our people, who are the foundation of our continued success. This event marked the beginning of a new chapter for Cosmo Pharmaceuticals. We aim to achieve remarkable growth and innovation while staying true to our core values. Thank you to everyone who made this day so memorable and for making Cosmo Pharmaceuticals not just a company, but a family. Together, we’re building something truly extraordinary! A special thank you to Pamela Tura Giacomo Facchini and Andrea Piccioni, who organized an outstanding event! #proudtobeCosmo #Leadership #GrowthJourney #TeamSpirit #CultureOfHappiness #CosmoLifesciences”

Here are highlights for “Lessons Learned in #AI for #HealthCare” from the visionary article by Andrea Cherubini from Cosmo Intelligent Medical Devices written for AI in Precision Oncology special issue on #cancerscreening 1. Transparency and Accountability: Developing AI in health care is a delicate balance between improving outcomes and addressing concerns about safety, data privacy, and ethics. Striking this balance requires transparency in AI development, rigorous validation, and adherence to established guidelines to build trust among stakeholders. Transparency in data sources and development processes fosters confidence in AI technologies. 2. Communication Between Stakeholders: Effective collaboration and communication between AI developers and health care professionals are essential for successful AI deployment. Clinician acceptance and integration of AI into their workflow are critical. Resistance to new technologies can be overcome with proper training and involvement. #Multidisciplinary #collaboration among AI experts, clinicians, and other stakeholders enhances the development and #adoption of AI #technologies. 3. Human-AI Interaction: For AI to be effective, it must work synergistically with #human expertise. The best results come from a "human-AI hybrid" model, where AI augments, rather than replaces, human decision-making. User-friendly interfaces and clear communication of AI’s limitations are key to ensuring that #physicians can effectively use AI to improve patient outcomes. These lessons highlight the importance of a #humancentered approach, transparency, and collaboration for the successful integration of AI in health care. Douglas Flora, MD, LSSBB, FACCC Nikhil Thaker, MD Mary Ann Liebert, Inc.

I’m thrilled to have participated in a dynamic panel discussion on the Impact of Regulations on AI Development in Gastroenterology at the 6th Annual Global Artificial Intelligence Summit, organized by the Artificial Intelligence Institute for Gastroenterology (AIGI). As AI continues to revolutionize healthcare, particularly in gastroenterology, navigating the complex landscape of regulations is crucial for its safe and effective implementation. Grateful to Prateek Sharma and Michael B Wallace MD MPH for organizing this important event and inviting me, Shani Haugen for providing insights on the FDA’s perspective on regulating AI medical devices, and Jonathan Cohen and Cesare Hassan for moderating the session. Raj Thomas Giovanni Di Napoli Monika McDole-Russell Jeffrey Potkul Austin Lee Chiang, MD MPH #AIinHealthcare #Gastroenterology #ArtificialIntelligence #AIGI #AIRegulation #FDA #InnovationInMedicine #FutureOfHealthcare

Cosmo Intelligent Medical Devices (Cosmo IMD), a division of Cosmo Pharmaceuticals N.V. (Cosmo) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the next generation GI Genius™ hardware, the latest development of the GI Genius™ intelligent endoscopy system, which Medtronic exclusively distributes globally. This milestone reaffirms the GI Genius™ platform’s leadership in AI-enhanced endoscopy and marks a significant advancement in the realm of medical technology. The GI Genius™ hardware, now in its sixth generation, is engineered to elevate physician performance with sophisticated AI-driven insights during patient procedures. This latest iteration includes the FDA-cleared ColonPRO™ software, the GI Genius™ AI colon application designed to help endoscopists identify potential polyps and standardize quality metric reporting during colorectal cancer screenings. These advancements were realized through Cosmo IMD’s meticulous engineering, utilizing state-of-the-art components such as NVIDIA IGX Orin™ and @NVIDIA Holoscan™ technologies. Revolutionary features of the latest GI Genius™ hardware Read more here: https://bit.ly/3Ws6Mkm Giovanni Di Napoli, Nhan Ngo Dinh, Andrea Cherubini, Hazel Winchester #Wearecosmo #GIGenius #medicaldevice #medicaltechnology #Cosmo #CosmoIMD #Medtronic #NVIDIA #Colonoscopy #Coloncancer #gastroenterology #AI #FDA

Cosmo Pharmaceuticals Reports Stellar Half-Year 2024 Results: I am delighted to share that Cosmo Pharmaceuticals has delivered outstanding half-year results for 2024. Our commitment to innovation and excellence continues to drive remarkable achievements. Here are some key highlights: Financial Performance: - **Revenue:** Reached an impressive €136.2 million, reflecting the strong market demand for our advanced pharmaceutical solutions. - **EBITDA:** Achieved a robust €94.2 million, underscoring our operational efficiency. - **Operating Profit:** Recorded at €87.0 million, showcasing our profitability. - **Net Cash Inflow:** Generated a significant €99.2 million from operating activities. - **Dividend:** Paid a €2.00 per share dividend for FY2023, rewarding our shareholders. Health Tech: - **GI Genius™ Expansion:** Our AI-enhanced endoscopy system continues to grow, with the new ColonPRO™ version approved by the FDA in January. This software incorporates an enhanced algorithm, significantly improving detection capabilities and automating physician workflows. **Dermatology Success:** - **Winlevi® Dominance:** Continues to be the #1 prescribed topical acne product in the U.S. The global expansion is on track with successful launches in Canada and Australia. Submissions for approval are ongoing in 14 additional countries, promising further growth. **Gastroenterology Growth:** - **Increased Shipments:** Our GI products have seen a surge in shipments to partners, reflecting our expanding market presence. **CDMO Growth:** - **Revenue Increase:** Our contract development and manufacturing organization (CDMO) division grew by 9.3%, driven by higher orders from existing customers. **Pipeline & Regulatory Highlights:** - **New Submissions:** GI Genius™ module 300 powered by Nvidia IGX has been submitted to the FDA for clearance. - **Clinical Trials:** Progressing well with key trials, including the Androgenetic Alopecia phase III trial and Distal Ulcerative Colitis phase II study. - **Global Approvals:** Lumeblue® New Drug Application approved in China, with our partner CMS preparing for the launch. These achievements underscore our relentless pursuit of quality and innovation, driving forward our mission to enhance healthcare outcomes worldwide. I am immensely proud of our team’s dedication and excited about the future prospects. Thank you to our incredible team, partners, and shareholders for your unwavering support. Together, we are shaping a brighter future at Cosmo Pharmaceuticals! https://lnkd.in/eFy54vUJ Cosmo Pharmaceuticals Andrea Cherubini Nhan Ngo Dinh Hazel Winchester #EarningsResults #Pharmaceuticals #Innovation #Healthcare #Growth #CosmoPharmaceuticals #TeamSuccess

Cosmo Pharmaceuticals Reports Stellar Half-Year 2024 Results: I am delighted to share that Cosmo Pharmaceuticals has delivered outstanding half-year results for 2024. Our commitment to innovation and excellence continues to drive remarkable achievements. Here are some key highlights: Financial Performance: - **Revenue:** Reached an impressive €136.2 million, reflecting the strong market demand for our advanced pharmaceutical solutions. - **EBITDA:** Achieved a robust €94.2 million, underscoring our operational efficiency. - **Operating Profit:** Recorded at €87.0 million, showcasing our profitability. - **Net Cash Inflow:** Generated a significant €99.2 million from operating activities. - **Dividend:** Paid a €2.00 per share dividend for FY2023, rewarding our shareholders. Health Tech: - **GI Genius™ Expansion:** Our AI-enhanced endoscopy system continues to grow, with the new ColonPRO™ version approved by the FDA in January. This software incorporates an enhanced algorithm, significantly improving detection capabilities and automating physician workflows. **Dermatology Success:** - **Winlevi® Dominance:** Continues to be the #1 prescribed topical acne product in the U.S. The global expansion is on track with successful launches in Canada and Australia. Submissions for approval are ongoing in 14 additional countries, promising further growth. **Gastroenterology Growth:** - **Increased Shipments:** Our GI products have seen a surge in shipments to partners, reflecting our expanding market presence. **CDMO Growth:** - **Revenue Increase:** Our contract development and manufacturing organization (CDMO) division grew by 9.3%, driven by higher orders from existing customers. **Pipeline & Regulatory Highlights:** - **New Submissions:** GI Genius™ module 300 powered by Nvidia IGX has been submitted to the FDA for clearance. - **Clinical Trials:** Progressing well with key trials, including the Androgenetic Alopecia phase III trial and Distal Ulcerative Colitis phase II study. - **Global Approvals:** Lumeblue® New Drug Application approved in China, with our partner CMS preparing for the launch. These achievements underscore our relentless pursuit of quality and innovation, driving forward our mission to enhance healthcare outcomes worldwide. I am immensely proud of our team’s dedication and excited about the future prospects. Thank you to our incredible team, partners, and shareholders for your unwavering support. Together, we are shaping a brighter future at Cosmo Pharmaceuticals! https://lnkd.in/eFy54vUJ Cosmo Pharmaceuticals Andrea Cherubini Nhan Ngo Dinh Hazel Winchester #EarningsResults #Pharmaceuticals #Innovation #Healthcare #Growth #CosmoPharmaceuticals #TeamSuccess

How Cosmo Pharmaceuticals cranked up the cancer-catching AI behind Medtronic’s GI Genius ColonPro: Cosmo Intelligent Medical Devices President Nhan Ngo Dinh and Science, AI and Data SVP Andrea Cherubini discuss how their team developed advanced machine learning algorithms for improved polyp detection and neural network for new features, the challenges they overcame and the technology advances that made it all possible. My first of three posts from this interview is live now at Medical Design & Outsourcing: https://lnkd.in/gw67sEj3

🌟 **Exciting Visit from Kimberly Powell at Cosmo Pharmaceuticals!** 🌟 This morning, we had the incredible honor of hosting Kimberly Powell Healthcare GM and VP for NVIDIA at our Cosmo Pharmaceuticals offices in Lainate. From the pictures, you can see the intensity and enthusiasm that filled the room as we delved into deep discussions about our current capabilities and explored future opportunities to strengthen our partnership. Our conversation spanned across various fronts, particularly focusing on the immense potential in the AI space beyond Gi Genius. We explored how #AI can revolutionize not just pharma but also enhance our manufacturing processes at Cosmo. This visit marks a significant step forward in our collaboration with Nvidia, and we are excited about the innovative paths we are paving together. The future looks incredibly promising, and we are eager to see the groundbreaking advancements that will emerge from this partnership. A big thank you to Kimberly Powell for her visit and inspiring insights. Here’s to pushing the boundaries of healthcare and technology together! 🚀 #AI #HealthcareInnovation #Partnership #Pharma #CosmoPharmaceuticals #Nvidia #FutureForward